Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
Capricor Therapeutics (NASDAQ: CAPR), a biotech company focused on developing cell and exosome-based therapeutics for rare diseases, has announced its participation in Leerink's Global Healthcare Conference 2025. The conference will take place from March 10-12, 2025, in Miami, Florida.
The company's management will engage in one-on-one investor meetings and deliver a corporate presentation on Wednesday, March 12, 2025, from 1:00-1:40 p.m. ET. During the presentation, Capricor will provide updates on their lead program deramiocel, which targets the treatment of Duchenne muscular dystrophy (DMD), along with other scientific and corporate developments.
Capricor Therapeutics (NASDAQ: CAPR), un'azienda biotecnologica focalizzata nello sviluppo di terapie a base di cellule ed esosomi per malattie rare, ha annunciato la sua partecipazione alla Global Healthcare Conference 2025 di Leerink. La conferenza si terrà dal 10 al 12 marzo 2025 a Miami, Florida.
La direzione dell'azienda parteciperà a incontri individuali con gli investitori e presenterà una relazione aziendale mercoledì 12 marzo 2025, dalle 13:00 alle 13:40 ET. Durante la presentazione, Capricor fornirà aggiornamenti sul loro programma principale deramiocel, che mira al trattamento della distrofia muscolare di Duchenne (DMD), insieme ad altri sviluppi scientifici e aziendali.
Capricor Therapeutics (NASDAQ: CAPR), una empresa biotecnológica centrada en el desarrollo de terapias basadas en células y exosomas para enfermedades raras, ha anunciado su participación en la Global Healthcare Conference 2025 de Leerink. La conferencia se llevará a cabo del 10 al 12 de marzo de 2025 en Miami, Florida.
La dirección de la empresa participará en reuniones individuales con inversores y realizará una presentación corporativa el miércoles 12 de marzo de 2025, de 1:00 a 1:40 p.m. ET. Durante la presentación, Capricor proporcionará actualizaciones sobre su programa principal deramiocel, que se enfoca en el tratamiento de la distrofia muscular de Duchenne (DMD), junto con otros desarrollos científicos y corporativos.
Capricor Therapeutics (NASDAQ: CAPR)는 희귀 질환을 위한 세포 및 엑소좀 기반 치료제를 개발하는 생명공학 회사로, Leerink의 글로벌 헬스케어 컨퍼런스 2025에 참여한다고 발표했습니다. 이 컨퍼런스는 2025년 3월 10일부터 12일까지 플로리다주 마이애미에서 열릴 예정입니다.
회사의 경영진은 투자자와의 일대일 회의에 참여하고 2025년 3월 12일 수요일 오후 1시부터 1시 40분 ET까지 기업 발표를 진행할 것입니다. 발표 중에 Capricor는 더라미오셀이라는 주요 프로그램에 대한 업데이트를 제공하며, 이는 뒤셴 근육 위축증(DMD) 치료를 목표로 하고 있으며, 기타 과학적 및 기업 발전에 대한 내용도 포함될 것입니다.
Capricor Therapeutics (NASDAQ: CAPR), une entreprise biopharmaceutique axée sur le développement de thérapies basées sur des cellules et des exosomes pour les maladies rares, a annoncé sa participation à la Global Healthcare Conference 2025 de Leerink. La conférence se déroulera du 10 au 12 mars 2025 à Miami, en Floride.
La direction de l'entreprise participera à des réunions individuelles avec des investisseurs et fera une présentation d'entreprise le mercredi 12 mars 2025, de 13h00 à 13h40 ET. Lors de cette présentation, Capricor fournira des mises à jour sur son programme phare deramiocel, qui cible le traitement de la , ainsi que d'autres développements scientifiques et d'entreprise.
Capricor Therapeutics (NASDAQ: CAPR), ein Biotech-Unternehmen, das sich auf die Entwicklung von Zell- und Exosom-basierten Therapeutika für seltene Krankheiten konzentriert, hat seine Teilnahme an der Global Healthcare Conference 2025 von Leerink angekündigt. Die Konferenz findet vom 10. bis 12. März 2025 in Miami, Florida, statt.
Das Management des Unternehmens wird an persönlichen Investorenmeetings teilnehmen und eine Unternehmenspräsentation am Mittwoch, den 12. März 2025, von 13:00 bis 13:40 Uhr ET halten. Während der Präsentation wird Capricor Updates zu ihrem Hauptprogramm deramiocel geben, das sich auf die Behandlung der Duchenne-Muskeldystrophie (DMD) konzentriert, sowie zu weiteren wissenschaftlichen und unternehmerischen Entwicklungen.
- None.
- None.
SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that Capricor management will participate in one-on-one investor meetings and provide a corporate update at Leerink’s Global Healthcare Conference 2025, taking place March 10-12, 2025 in Miami, Florida.
Leerink’s Global Healthcare Conference 2025
- Presentation Date: Wednesday, March 12, 2025
- Time: 1:00-1:40 p.m. ET
- Webcast: Click here
Capricor management will present updates on its lead program of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) as well as provide other general scientific and corporate updates. For further information on this presentation, please visit Capricor's website at http://capricor.com/news/events/.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, deramiocel, an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown deramiocel to demonstrate immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. Deramiocel is currently in late-stage development for the treatment of Duchenne muscular dystrophy. Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases. At Capricor, we stand committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and Twitter.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; statements about our financial outlook; the ability to achieve product milestones and to receive milestone payments from commercial partners; plans regarding current and future collaborative activities and the ownership of commercial rights; potential future agreements; scope, duration, validity and enforceability of intellectual property rights; future revenue streams and projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on March 11, 2024, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on November 14, 2024. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
Capricor has entered into an agreement for the exclusive commercialization and distribution of deramiocel (CAP-1002) for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.), subject to regulatory approval. Deramiocel is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation.
For more information, please contact:
Capricor Media Contact:
Raquel Cona
KCSA Strategic Communications
rcona@kcsa.com
212.896.1204
Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755
FAQ
When is Capricor Therapeutics (CAPR) presenting at Leerink's Healthcare Conference 2025?
What will be the main focus of CAPR's presentation at the Leerink Conference 2025?
What type of meetings will CAPR management conduct at the Leerink Conference 2025?
What is the primary therapeutic focus of CAPR's development pipeline?
